0000950170-25-044801.txt : 20250326 0000950170-25-044801.hdr.sgml : 20250326 20250326080508 ACCESSION NUMBER: 0000950170-25-044801 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250321 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORGANOVO HOLDINGS, INC. CENTRAL INDEX KEY: 0001497253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 271488943 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35996 FILM NUMBER: 25770235 BUSINESS ADDRESS: STREET 1: 11555 SORRENTO VALLEY ROAD STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-224-1000 MAIL ADDRESS: STREET 1: 11555 SORRENTO VALLEY ROAD STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: REAL ESTATE RESTORATION & RENTAL, INC. DATE OF NAME CHANGE: 20100722 8-K 1 onvo-20250321.htm 8-K 8-K
0001497253false00014972532025-03-212025-03-21

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 21, 2025

 

 

Organovo Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35996

27-1488943

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

11555 Sorrento Valley Rd

Suite 100

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 224-1000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

ONVO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

As previously disclosed in the Current Report on Form 8-K filed by Organovo Holdings, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “SEC”) on February 25, 2025, the Company entered into an asset purchase agreement dated February 23, 2025 (the “Purchase Agreement”) with Eli Lilly and Company, an Indiana corporation (“Lilly”), for the sale to and purchase by Lilly of the Company’s FXR program and related assets (the “Asset Sale”).

On March 25, 2025, the Company and Lilly completed the Asset Sale. The consideration for the Asset Sale consists of (i) an upfront cash payment by Lilly to the Company equal to $10.0 million, of which $9.0 million was paid at closing and the remaining $1.0 million was deposited into escrow for 15 months to satisfy any claims for indemnification during such period under the Purchase Agreement, (ii) the assumption by Lilly of certain liabilities related to the FXR program, and (iii) potential milestone payments by Lilly of up to $50.0 million in the aggregate, which are contingent upon the achievement of certain development, regulatory and commercial milestones. In connection with the completion of the Asset Sale, the parties entered into a transition services agreement and certain other ancillary agreements.

The foregoing description of the terms of the Purchase Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the complete text of the Purchase Agreement, which was previously filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2025, and is incorporated herein by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 21, 2025, Vaidehi Joshi notified the Board of Directors (the “Board”) of the Company that she resigned from the Board and all committees of the Board, effective as of March 21, 2025. Ms. Joshi’s decision to resign was not due to any disagreements with the Company on any matter relating to the Company’s operations, policies or practices.

Item 8.01 Other Events.

On March 25, 2025, the Company issued a press release announcing the closing of the Asset Sale. The press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

 

 

 

Exhibit

No.

Description

2.1* Asset Purchase Agreement, dated February 23, 2025, by and between the Company, Eli Lilly and for certain sections therein, Organovo, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company with the SEC on February 25, 2025).

99.1 Press Release, dated March 25, 2025.

104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

* Portions of this exhibit (indicated by [… * * *…]) have been omitted because the Company has determined that the information is both (i) not material and (ii) of the type that the Company treats as private and confidential. In addition, schedules have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for any schedule so furnished.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ORGANOVO HOLDINGS, INC.

 

 

 

 

Date:

March 26, 2025

By:

 /s/ Keith Murphy

 

 

 

Name: Keith Murphy
Title: Executive Chairman

 

 EX-99.1 2 onvo-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

 

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

 

San Diego, CA – March 25, 2025 – Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025.

 

With the closing, Organovo receives an upfront payment, with future milestones to be paid as FXR314 hits key regulatory and commercial milestones. Lilly is acquiring all commercial and intellectual property rights to Organovo’s FXR program for worldwide development and will be responsible for all future clinical development.

 

About Organovo

Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. For more information visit Organovo's website at www.organovo.com.

 

Forward Looking Statements

Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 19, 2025 and the Registration Statement on Form S-1 (File No. 333-282841). You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.

 

Contact

 

Investor Relations

info@organovo.com

img73928077_0.gif

img73928077_1.jpg

Source: Organovo, Inc.

 

 GRAPHIC 3 img73928077_0.gif GRAPHIC begin 644 img73928077_0.gif K1TE&.#EA 0 ! ( -O?[P "'Y! $ + ! $ ("1 $ .P$! end GRAPHIC 4 img73928077_1.jpg GRAPHIC begin 644 img73928077_1.jpg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end EX-101.SCH 5 onvo-20250321.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 7 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document And Entity Information
Mar. 21, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 21, 2025
Entity Registrant Name Organovo Holdings, Inc.
Entity Central Index Key 0001497253
Entity Emerging Growth Company false
Entity File Number 001-35996
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 27-1488943
Entity Address, Address Line One 11555 Sorrento Valley Rd
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 224-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol ONVO
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports onvo-20250321.htm onvo-20250321.xsd http://xbrl.sec.gov/dei/2024 false false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "onvo-20250321.htm": { "nsprefix": "onvo", "nsuri": "http://www.organovo.com/20250321", "dts": { "inline": { "local": [ "onvo-20250321.htm" ] }, "schema": { "local": [ "onvo-20250321.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_871aa1fe-df59-4b41-9039-2a3fb90c6633", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20250321.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_871aa1fe-df59-4b41-9039-2a3fb90c6633", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "onvo-20250321.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.organovo.com/20250321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000950170-25-044801-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-25-044801-xbrl.zip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end XML 16 onvo-20250321_htm.xml IDEA: XBRL DOCUMENT 0001497253 2025-03-21 2025-03-21 0001497253 false 8-K 2025-03-21 Organovo Holdings, Inc. DE 001-35996 27-1488943 11555 Sorrento Valley Rd Suite 100 San Diego CA 92121 (858) 224-1000 false false false false Common Stock, $0.001 par value ONVO NASDAQ false